OBJECTIVE: The aim of our study was to investigate the effects of multiple doses of paroxetine on the pharmacokinetics, safety, and tolerability of a single oral 10-microg dose of ramosetron. METHODS This was an open, one-sequence crossover design study. On day 1, healthy male and female subjects were administered a single dose of 10 microg ramosetron. On the morning of day 3, the subjects were administered paroxetine to reach steady state, which consisted of morning doses of 20 mg on days 3-12. The dose on day 11 was administered in combination with a single dose of 10 microg ramosetron. RESULTS: In subjects genotyped as extensive CYP2D6 metabolizers, coadministration of paroxetine with ramosetron resulted in an increase in area under the curve from 0 to infinity (AUC(0-inf)) and the peak concentration (Cmax) of ramosetron by 1.14-fold (90% confidence interval (CI): 1.07-1.22) and by 1.06-fold (90% CI: 1.00-1.11), respectively. CONCLUSIONS: It can be concluded that the single-dose pharmacokinetic profile of ramosetron 10 microg is not affected to a clinically relevant degree by paroxetine 20 mg once daily administered for 10 days.
OBJECTIVE: The aim of our study was to investigate the effects of multiple doses of paroxetine on the pharmacokinetics, safety, and tolerability of a single oral 10-microg dose of ramosetron. METHODS This was an open, one-sequence crossover design study. On day 1, healthy male and female subjects were administered a single dose of 10 microg ramosetron. On the morning of day 3, the subjects were administered paroxetine to reach steady state, which consisted of morning doses of 20 mg on days 3-12. The dose on day 11 was administered in combination with a single dose of 10 microg ramosetron. RESULTS: In subjects genotyped as extensive CYP2D6 metabolizers, coadministration of paroxetine with ramosetron resulted in an increase in area under the curve from 0 to infinity (AUC(0-inf)) and the peak concentration (Cmax) of ramosetron by 1.14-fold (90% confidence interval (CI): 1.07-1.22) and by 1.06-fold (90% CI: 1.00-1.11), respectively. CONCLUSIONS: It can be concluded that the single-dose pharmacokinetic profile of ramosetron 10 microg is not affected to a clinically relevant degree by paroxetine 20 mg once daily administered for 10 days.
Authors: Francis Creed; Lakshmi Fernandes; Elspeth Guthrie; Stephen Palmer; Joy Ratcliffe; Nicholas Read; Christine Rigby; David Thompson; Barbara Tomenson Journal: Gastroenterology Date: 2003-02 Impact factor: 22.682
Authors: K M Koch; B W Corrigan; J Manzo; C D James; R J Scott; A G Stead; K E Kersey Journal: Aliment Pharmacol Ther Date: 2004-07-15 Impact factor: 8.171
Authors: G C Bell; K E Caudle; M Whirl-Carrillo; R J Gordon; K Hikino; C A Prows; A Gaedigk; Jag Agundez; S Sadhasivam; T E Klein; M Schwab Journal: Clin Pharmacol Ther Date: 2017-04-06 Impact factor: 6.875